

Ana C Medeiros-Ribeiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1037800/publications.pdf>

Version: 2024-02-01

22
papers

546
citations

840119

11
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

705
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. <i>Nature Medicine</i> , 2021, 27, 1744-1751.	15.2	148
2	Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 476-480.	1.5	95
3	Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 889-897.	0.5	42
4	Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. <i>Lancet HIV</i> , 2022, 9, e323-e331.	2.1	36
5	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1036-1043.	0.5	30
6	Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 562-571.	1.5	25
7	Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. <i>Lancet Rheumatology</i> , 2022, 4, e113-e124.	2.2	24
8	Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 49-56.	2.0	18
9	Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 710-719.	0.5	16
10	Dry eye in rheumatoid arthritis patients under TNF-inhibitors: conjunctival goblet cell as an early ocular biomarker. <i>Scientific Reports</i> , 2020, 10, 14054.	1.6	13
11	Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. <i>Rheumatology</i> , 2022, 61, 3351-3361.	0.9	13
12	Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 974-984.	0.8	13
13	Predictors of progression to systemic sclerosis: analysis of very early diagnosis of systemic sclerosis in a large single-centre cohort. <i>Rheumatology</i> , 2022, 61, 3686-3692.	0.9	12
14	Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 151987.	1.6	12
15	Is exposure to environmental factors associated with a characteristic clinical and laboratory profile in systemic sclerosis? A retrospective analysis. <i>Rheumatology International</i> , 2021, 41, 1143-1150.	1.5	11
16	SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. <i>Rheumatology</i> , 2022, 61, S1169-S1174.	0.9	9
17	Safety of the Methotrexate-leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil). <i>Journal of Rheumatology</i> , 2021, 48, 1519-1527.	1.0	8
18	Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity. <i>Clinical Rheumatology</i> , 2022, 41, 2079-2089.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010002.	1.3	5
20	Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area. <i>Clinics</i> , 2020, 75, e1870.	0.6	4
21	Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control. <i>Clinical Rheumatology</i> , 2020, 39, 1747-1755.	1.0	3
22	Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients. <i>Journal of Applied Physiology</i> , 2022, 132, 682-688.	1.2	2